Patent · US Active

Bispecific T cell activating antigen binding molecules

US11117965B2 · kind B2 · utility

2Cited by

30References

35Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Oliver Ast · Bassersdorf, CH
Marina BACAC · Schlieren, CH
Sabine Imhof-Jung · Planegg, DE
Christiane Neumann · Niederweningen, CH
Christian Klein · Iffeldorf, DE
Stefan Klostermann · Schwanau, DE
Michael Molhoj · Munich, DE
Joerg Thomas Regula · Munich, DE
Wolfgang Schaefer · Sankt Augustin, DE
Pablo Umana · Wollerau, CH

Key dates

Filing date	Feb 24, 2020
Grant date	Sep 14, 2021
Priority date	—
Expiry date	Feb 24, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.